Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
17%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
5
63%
Ph phase_2
3
38%

Phase Distribution

5

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
3(37.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(6)
Terminated(2)

Detailed Status

Completed6
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (62.5%)
Phase 23 (37.5%)

Trials by Status

withdrawn113%
completed675%
terminated113%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_2

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
completedphase_1

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

NCT00785915
withdrawnphase_1

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

NCT00963365
completedphase_1

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

NCT01046630
completedphase_1

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

NCT01069822
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00986479Phase 2

This is a Study to Determine the Antidepressant Effects of AZD6765

Completed
NCT00785915Phase 1

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

Completed
NCT00963365Phase 1

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Withdrawn
NCT01046630Phase 1

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Completed
NCT01069822Phase 1

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

Completed
NCT01130909Phase 1

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Terminated
NCT00781742Phase 2

AZD6765 Severe Major Depressive Disorder (MDD) IV

Completed
NCT00491686Phase 2

AZD6765 for Treatment Resistant Depression

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8